Steriwave ICU Pilot Study

This is a single-center, non-blinded, prospective, pilot study enrolling patients admitted to the critical care unit at Royal Columbian Hospital. This study investigates the effects of universal nasal decolonization using antimicrobial photodynamic therapy (aPDT) on the prevention of hospital-acquired pneumonia (HAP), ventilator-acquired pneumonia (VAP), and hospital-acquired bloodstream infection (BSI) in this patient population. Main Objectives include: * To determine whether a large, multi-center RCT of this protocol is feasible * To determine baseline rates of VAP, HAP, and ICU-acquired BSI * To gather preliminary efficacy data regarding VAP, HAP, and ICU-acquired BSI prevention using universal aPDT nasal decolonization * To gather preliminary microbiological data on the effect of universal aPDT procedures on nasal carriage of various microoganisms in ICU patients.

NCT Number	NCT06867458
Lead Sponsor	Fraser Health Collaborators: Ondine Biomedical Inc., Royal Columbian Hospital Foundation
Conditions	Ventilator Acquired Pneumonia, Hospital Acquired Pneumonia, Hospital Acquired Infections, Nasal Decolonization of Staphylococcus Aureus
Enrollment	227 participants
Start Date	2025-03-18
Primary Completion	2025-07-18 (estimated)
Study Completion	2025-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-03-05